BTTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BTTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Better Therapeutics's interest expense for the three months ended in Sep. 2023 was $ -0.52 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.95 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Better Therapeutics's Operating Income for the three months ended in Sep. 2023 was $ -5.34 Mil. Better Therapeutics's Interest Expense for the three months ended in Sep. 2023 was $ -0.52 Mil. Better Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Better Therapeutics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Better Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Interest Expense | -0.01 | -0.10 | -0.19 | -1.49 |
Better Therapeutics Quarterly Data | ||||||||||||||
Dec19 | Jun20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Interest Expense | Get a 7-Day Free Trial | -0.41 | -0.44 | -0.43 | -0.56 | -0.52 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Better Therapeutics (OTCPK:BTTX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Better Therapeutics's Interest Expense for the three months ended in Sep. 2023 was $-0.52 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-5.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $7.72 Mil.
Better Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
Better Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Elder Granger | director | 5176 S. LEWISTON WAY, CENTENNIAL CO 80015 |
Mark A. Berman | officer: Chief Medical Officer | 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Geoffrey M. Parker | director | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Frank Karbe | director, officer: See Remarks | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David P Perry | director, 10 percent owner, officer: See Remarks | 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Andrew J. Armanino | director | C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612 |
Georgianna Maule-ffinch 2015 Trust | 10 percent owner | C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Mark Heinen | officer: See Remarks | 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Risa J Lavizzo-mourey | director | GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661 |
Kevin J Appelbaum | director, 10 percent owner, officer: Chief Executive Officer | 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568 |
Suying Liu | director | 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036 |
Justin Zamirowski | officer: Chief Commercial Officer | 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Kristin Wynholds | officer: Chief Product Officer | 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Richard H Carmona | director | 1221 BROADWAY, OAKLAND CA 94612 |
David P. Perry 2015 Trust | 10 percent owner | 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
From GuruFocus
By Business Wire Business Wire • 07-11-2022
By Business Wire Business Wire • 07-26-2022
By Business Wire • 08-02-2023
By Business Wire • 08-09-2023
By PRNewswire PRNewswire • 07-13-2022
By Business Wire • 10-05-2023
By Business Wire Business Wire • 11-15-2022
By Business Wire • 11-28-2023
By Business Wire Business Wire • 10-27-2022
By Business Wire • 11-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.